Humacyte (NASDAQ:HUMA) Stock Price Up 7.4%

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report)'s stock price rose 7.4% during trading on Wednesday . The company traded as high as $4.21 and last traded at $4.21. Approximately 681,666 shares changed hands during mid-day trading, a decline of 39% from the average daily volume of 1,110,118 shares. The stock had previously closed at $3.92.

Wall Street Analyst Weigh In

HUMA has been the subject of a number of research reports. Benchmark reiterated a "buy" rating and issued a $15.00 price target on shares of Humacyte in a research note on Monday, March 25th. Piper Sandler restated a "neutral" rating and issued a $4.00 target price on shares of Humacyte in a research note on Tuesday, March 26th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $7.00 target price on shares of Humacyte in a research note on Monday, April 1st.

Humacyte Stock Performance

The company has a quick ratio of 4.52, a current ratio of 4.52 and a debt-to-equity ratio of 1.20. The company has a 50-day moving average price of $3.48 and a 200-day moving average price of $3.05. The firm has a market capitalization of $523.97 million, a price-to-earnings ratio of -4.11 and a beta of 1.46.

Humacyte (NASDAQ:HUMA - Get Free Report) last issued its quarterly earnings data on Friday, March 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.01. During the same period last year, the company earned ($0.21) EPS. As a group, equities research analysts forecast that Humacyte, Inc. will post -0.9 earnings per share for the current year.

Institutional Investors Weigh In On Humacyte

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Capstone Investment Advisors LLC bought a new position in shares of Humacyte in the first quarter valued at $972,000. Private Advisor Group LLC raised its stake in Humacyte by 232.7% during the 1st quarter. Private Advisor Group LLC now owns 317,624 shares of the company's stock valued at $988,000 after purchasing an additional 222,144 shares during the period. GSA Capital Partners LLP raised its stake in Humacyte by 139.5% during the 3rd quarter. GSA Capital Partners LLP now owns 355,918 shares of the company's stock valued at $1,043,000 after purchasing an additional 207,333 shares during the period. Rokos Capital Management LLP raised its stake in Humacyte by 122.5% during the 3rd quarter. Rokos Capital Management LLP now owns 200,000 shares of the company's stock valued at $587,000 after purchasing an additional 110,097 shares during the period. Finally, Clough Capital Partners L P acquired a new stake in Humacyte during the 3rd quarter valued at $232,000. Institutional investors own 44.71% of the company's stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.